Bifunctional PROTAC Compounds Degrade KRAS-G12D to Overcome Drug Resistance
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current KRAS inhibitors face significant limitations, particularly the emergence of drug resistance in treating KRAS-associated diseases, necessitating new approaches that can maintain efficacy and overcome resistance mechanisms.
Innovation Solution
Development of bifunctional proteolysis targeting chimera (Protac) compounds that bind to both KRAS-G12D protein and an E3 ligase, promoting ubiquitination and subsequent degradation of the target protein, rather than solely inhibiting enzymatic activity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If traditional KRAS inhibitors are used to block KRAS-G12D enzymatic activity, then initial treatment efficacy is achieved, but acquired drug resistance emerges over time
Solution Approach 1:
Instead of inhibiting KRAS-G12D enzymatic activity directly (traditional approach), the invention inverts the strategy by promoting the degradation of the KRAS-G12D protein itself through PROTAC-mediated ubiquitination, thereby eliminating the target rather than blocking its function
Solution Approach 2:
The invention introduces an intermediary mechanism (PROTAC compound) that mediates between the inhibitor and the target protein. The PROTAC acts as a bridge that recruits E3 ubiquitin ligase to ubiquitinate and degrade KRAS-G12D, providing a more robust and durable treatment approach that overcomes resistance
2Productivity
If KRAS-G12D enzymatic activity is inhibited, then tumor growth is initially suppressed, but cellular heterogeneity and secondary mutations lead to resistance
Solution Approach 1:
The invention takes preliminary action by degrading the KRAS-G12D protein before it can acquire resistance mutations or adapt to inhibition. By eliminating the target protein itself rather than merely inhibiting its activity, the treatment prevents the development of resistant clones
Solution Approach 2:
The invention changes the fundamental parameter of target engagement from enzymatic activity inhibition to protein degradation. This parameter change from functional inhibition to physical elimination of the target protein provides more durable and adaptable treatment that overcomes tumor heterogeneity and resistance mechanisms
3Device complexity
If direct binding inhibitors are used to block KRAS-G12D, then the mechanism is simple, but the approach fails to account for wild-type RAS activation by multiple RTKs
Solution Approach 1:
The PROTAC compound provides universal coverage by targeting KRAS-G12D protein degradation rather than specifically blocking enzymatic activity. This multi-functional approach addresses not only mutant KRAS but also has potential implications for wild-type RAS pathways activated by multiple RTKs, providing broader therapeutic coverage
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
These compounds effectively modulate the degradation of KRAS-G12D, offering potential as therapeutic or prophylactic agents for KRAS-related diseases, including cancers, by reducing the likelihood of acquired drug resistance and providing a new paradigm for targeting previously undruggable proteins.
Implementation Method 1
promoting ubiquitination and subsequent degradation of the target protein
Implementation Method 2
acts by inducing intracellular protein hydrolysis (proteolysis)
Data Source
AI summary
The disclosure relates to bifunctional KRAS-G12D-modulating compounds having the structure W-L-T, where W is a targeting group that binds specifically to KRAS-G12D protein, T is an E3-ligase binding group, and L is absent or is a bivalent linking group that connects W and T together via a covalent linkage. Compounds and pharmaceutical compositions thereof can promote degradation of the KRAS-G12D protein in a cell and are thus useful for treating, inhibiting, and preventing KRAS-G12D-associated diseases, disorders and conditions, including cancers.